-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The American Society of Clinical Oncology (ASCO) annual meeting is one of the most authoritative academic exchange events in the global oncology field
Hengrui Medicine: camrelizumab, apatinib
Hengrui Medicine: camrelizumab, apatinibMechanism of action: anti-PD-1 monoclonal antibody, VEGFR-2 tyrosine kinase inhibitor
Mechanism of action: anti-PD-1 monoclonal antibody, VEGFR-2 tyrosine kinase inhibitorIndications: melanoma, head and neck tumors, digestive tract tumors, etc.
Indications: melanoma, head and neck tumors, digestive tract tumors, etc.
At this conference, two studies of camrelizumab + apatinib combination therapy (hereinafter referred to as "Double Ai" combination) were selected for oral presentation: one is a single-center, single-arm phase 2 study, which aims to evaluate The efficacy of the "Shuangai" combination combined with temozolomide for injection in the first-line treatment of advanced acral melanoma; the other is a prospective single-arm study using the "Shuangai" combination in the treatment of patients with advanced mucosal melanoma
In the field of head and neck tumors, Hengrui Medicine has selected 4 studies, namely: a prospective, single-arm, open-label phase 2 clinical study evaluating chemotherapy-induced sequential concurrent chemoradiotherapy combined with "Shuangai" combination in the treatment of high risk of distant metastasis Efficacy and safety of nasopharyngeal carcinoma; Phase 2 clinical study of "Shuangai" combination in the treatment of recurrent or metastatic nasopharyngeal carcinoma; Apatinib in the treatment of locally advanced or metastatic radioactive iodine-resistant differentiated thyroid cancer Post hoc analysis; a single-arm, phase 2 IMplus study of the "Shuangai" combination in induction therapy for locally advanced head and neck squamous cell carcinoma
In addition, camrelizumab and apatinib have also been selected for 3 studies in the field of digestive tract, including: a prospective, single-arm, phase 2 trial using "Shuangai" combined with hepatic arterial infusion chemotherapy in the treatment of liver cancer; A single-arm, prospective, real-world study to evaluate the effect of transarterial chemoembolization combined with camrelizumab plus TKI targeted drugs in the treatment of unresectable liver cancer in the medium term; and a first-line treatment of "Shuangai" combined with chemotherapy A single-arm, dose escalation and extension study in advanced gastric/gastroesophageal junction cancer
Nuocheng Jianhua: gunagratinib, ICP-723, orbrutinib
Nuocheng Jianhua: gunagratinib, ICP-723, orbrutinibMechanism of action: FGFR 1-4 inhibitors, pan-TRK inhibitors, BTK inhibitors
Mechanism of action: FGFR 1-4 inhibitors, pan-TRK inhibitors, BTK inhibitorsIndications: head and neck cancer, solid tumors, diffuse large B-cell lymphoma
Indications: head and neck cancer, solid tumors, diffuse large B-cell lymphomaAccording to the press release of Nuocheng Jianhua, the latest data of the company's gunagratinib (ICP-192), ICP-723 and orelabrutinib and other pipelines under development were selected for the 2022 ASCO annual meeting
At this conference, the selected studies of Nuocheng Jianhua include: the clinical phase 1 data of gunagratinib in the treatment of FGF/FGFR gene-altered head and neck cancer patients will be published in the form of posters; the safety and drug efficacy of ICP-723 in patients with solid tumors Kinetic properties and clinical efficacy will be published as posters; real-world data analysis of efficacy and safety of orelabrutinib in diffuse large B-cell lymphoma will be published online
Rongchang Bio: Vidicitumumab
Rongchang Bio: VidicitumumabMechanism of Action: Anti-HER2 Antibody Conjugates
Mechanism of Action: Anti-HER2 Antibody ConjugatesIndications: urothelial carcinoma, HER2-expressing solid tumors
Indications: urothelial carcinoma, HER2-expressing solid tumorsAccording to Rongchang Bio’s press release, three latest clinical studies of the company’s self-developed anti-HER2 antibody-drug conjugate (ADC) Vidicitumab were selected for the 2022 ASCO Annual Meeting, and will constitute Vidicitumab at the same time.
At this conference, three clinical studies of Vidicitumab in the treatment of urothelial carcinoma were selected, namely: Vidicitumab combined with toripalimab in the treatment of locally advanced or metastatic urothelial carcinoma.
In addition, a new pan-tumor treatment model of vellicitumab was also selected for this conference, that is, the study of vellicitumab combined with radiotherapy and immunotherapy for HER2-expressing advanced and refractory solid tumors (Prague 3.
Henlius: Slulimumab
Henlius: SlulimumabMechanism of action: anti-PD-1 monoclonal antibody
Mechanism of action: anti-PD-1 monoclonal antibodyIndications: small cell lung cancer, MSI-H solid tumors
Indications: small cell lung cancer, MSI-H solid tumorsAccording to a Henlius press release, three studies of the anti-PD-1 monoclonal antibody slulimumab developed by the company have been selected for the 2022 ASCO Annual Meeting
At this conference, 3 studies of slulimumab were selected, namely: 1) The international multi-center phase 3 clinical study (ASTRUM-005 study) of slulimumab against first-line extensive-stage small cell lung cancer was selected as the oral Report; 2) The data update of the pivotal registrational Phase 2 clinical study (ASTRUM-010 study) of slulimumab against microsatellite highly unstable solid tumors was selected as a poster presentation; 3) A study of slulimumab against A phase 1 clinical study of advanced solid tumors, selected for the 2022 ASCO annual meeting abstract
CSPC: 5 products including KN026
CSPC: 5 products including KN026Mechanism of action: anti-HER2 double antibody, cytotoxic drugs
Mechanism of action: anti-HER2 double antibody, cytotoxic drugsIndications: gastric cancer, breast cancer, peripheral T-cell lymphoma, etc.
Indications: gastric cancer, breast cancer, peripheral T-cell lymphoma, etc.
KN026 was selected for this ASCO poster with the title: Phase 2 study of KN026 in late-line treatment of advanced HER2-expressing gastric or gastroesophageal junction cancer
At this conference, CSPC also has a number of studies selected
.
Among them, the studies to be published online are: 1) Phase 1b clinical study of mitoxantrone hydrochloride liposome injection in the treatment of recurrent/metastatic head and neck squamous cell carcinoma; 2) Different dosing regimens of paclitaxel for injection (albumin-bound) Phase 2 randomized controlled clinical study in the treatment of HER-2 negative recurrent/metastatic breast cancer; 3) Multicenter, randomized controlled study of pegylated recombinant human granulocyte stimulating factor injection for primary prevention of breast cancer patients
.
The selected studies in the ASCO poster include: 1) Phase 1b clinical study of mitoxantrone hydrochloride liposome injection in the treatment of platinum-refractory or platinum-resistant recurrent ovarian cancer; 2) combination of doxorubicin hydrochloride-containing liposome injection Phase 1 clinical study of the regimen in the treatment of children with cancer; 3) A national multi-center, randomized controlled comparison of paclitaxel for injection (albumin-bound) combined with Seggio versus standard regimen oxaliplatin + capecitabine for adjuvant treatment of gastric cancer research
.
In recent years, the field of biomedicine has made great progress in tumor treatment.
Innovative therapies such as small molecule targeted therapy, immunotherapy, RNA therapy, and cell therapy have all achieved therapeutic breakthroughs in the field of tumor
.
It is believed that in the near future, we will see the birth of more innovative therapies that will bring clinical benefits to cancer patients
.
We will also continue to follow this ASCO meeting to share more cutting-edge developments in the field of cancer research, and look forward to hearing the latest research progress from more biopharmaceutical companies
.
References:
References: [1] 2022 ASCO Prospect | Hengrui Medicine's "Shuangai" combination research was selected for oral and poster reports.
Retrieved Apr 7, 2022, from https://mp.
weixin.
qq.
com/s/_GT0x_5vlaUCI5ru57SNYg
Retrieved Apr 7, 2022, from https://mp.
weixin.
qq.
com/s/_GT0x_5vlaUCI5ru57SNYg
[2] Rare! Three blockbuster studies of vedicitumab were shortlisted for the 2022 ASCO annual meeting, forming a panel discussion.
Retrieved Apr 7, 2022.
From https://mp.
weixin.
qq.
com/s/OlKZpXJU5DVaoOHQA3gjTQ
Retrieved Apr 7, 2022.
From https://mp.
weixin.
qq.
com/s/OlKZpXJU5DVaoOHQA3gjTQ
[3] A new pan-tumor therapy model of vedicetumab (RC48-ADC) will be unveiled at 2022ASCO.
Retrieved Apr 14, 2022.
From https://mp.
weixin.
qq.
com/s/3DBc5ZLymRxpBPWv8QMSEw
Retrieved Apr 14, 2022.
From https://mp.
weixin.
qq.
com/s/3DBc5ZLymRxpBPWv8QMSEw
[4] Keeping upright and innovative, data first | H drug Hans-like multiple trials were selected for ASCO, domestic PD-1 monoclonal antibody will be the first oral report in the field of lung cancer.
Retrieved Apr 14, 2022.
From https://mp.
weixin .
qq.
com/s/0nWgy5ZLguCUOAY9_EqSiw
Retrieved Apr 14, 2022.
From https://mp.
weixin .
qq.
com/s/0nWgy5ZLguCUOAY9_EqSiw
[5] Three more innovative drug research results from CSPC were selected for the ASCO Annual Meeting.
Retrieved Apr 18 , 2022.
From https://mp.
weixin.
qq.
com/s/y5apjqR_JPApsUIcrAWWhw
Retrieved Apr 18 , 2022.
From https://mp.
weixin.
qq.
com/s/y5apjqR_JPApsUIcrAWWhw
[6] Four research results of CSPC were selected for the annual meeting of American Society of Clinical Oncology (ASCO).
Retrieved Apr 19 , 2022.
From https://mp.
weixin.
qq.
com/s/aXO7kgV-yD3dPe3fJrYLTA
Retrieved Apr 19 , 2022.
From https://mp.
weixin.
qq.
com/s/aXO7kgV-yD3dPe3fJrYLTA
[7] The 2022 American Society of Clinical Oncology (ASCO) annual meeting will announce the latest data of a series of pipelines under development of Nuocheng Jianhua.
Retrieved Apr 19 , 2022.
From https://mp.
weixin.
qq.
com/s/aPDGWCBz4tU_Ma3DPtGPxQ
Retrieved Apr 19 , 2022.
From https://mp.
weixin.
qq.
com/s/aPDGWCBz4tU_Ma3DPtGPxQ
